Cytokines, adipocytokines and inflammatory markers in patients on continuous ambulatory peritoneal dialysis and hemodialysis

Basit Öğe Kaydı
dc.contributor.authorOncel, Mufide
dc.contributor.authorAkbulut, Seval
dc.contributor.authorOzer, Turkan Toka
dc.contributor.authorKiyici, Aysel
dc.contributor.authorKeles, Mustafa
dc.contributor.authorBaltaci, Beyhan
dc.contributor.authorTurk, Suleyman
dc.date.accessioned2020-03-26T19:23:30Z
dc.date.available2020-03-26T19:23:30Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Cytokines are essential mediators of immune response. Chronic renal failure patients suffer from chronic inflammation that results from factors such as impaired renal function, accumulation of uremic toxins and bio incompatibility of dialyzer membranes. These patients are also at increased risk of cardiovascular diseases. We have evaluated cytokines, adipocytokines and inflammatory markers in patients with chronic renal failure undergoing hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD).Material and methods: We have determined serum tumor necrosis factor- (TNF-), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), leptin and ghrelin levels of chronic renal failure patients treated with either HD (n=20) or CAPD (n=20). TNF-, IL-6, ghrelin and leptin measurements were performed by commercially available kits based on enzyme-linked immunosorbent assay (ELISA) method. hsCRP levels were determined by turbidimetric methods.Results: Serum TNF- and IL-6 levels of patients on HD were significantly higher than those of the ones on CAPD (p<0.05). Ghrelin, leptin and hsCRP concentrations were similar in both groups.Conclusions: We can conclude that cytokine production is more obvious in HD process.en_US
dc.identifier.doi10.1080/0886022X.2016.1193874en_US
dc.identifier.endpage1075en_US
dc.identifier.issn0886-022Xen_US
dc.identifier.issn1525-6049en_US
dc.identifier.issue7en_US
dc.identifier.pmid27267129en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1071en_US
dc.identifier.urihttps://dx.doi.org/10.1080/0886022X.2016.1193874
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33412
dc.identifier.volume38en_US
dc.identifier.wosWOS:000382175000008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofRENAL FAILUREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdipocytokinesen_US
dc.subjectcontinuous ambulatory peritoneal dialysisen_US
dc.subjectcytokinesen_US
dc.subjecthemodialysisen_US
dc.subjecthsCRPen_US
dc.titleCytokines, adipocytokines and inflammatory markers in patients on continuous ambulatory peritoneal dialysis and hemodialysisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu